Defects in the striatal neuropeptide y system in X-linked dystonia-parkinsonism

Brain

Volumn 136, Issue 5, 2013, Pages 1555-1567

  Goto, Satoshi ^a,b   Kawarai, Toshitaka ^b   Morigaki, Ryoma ^a,b   Okita, Shinya ^a,b   Koizumi, Hidetaka ^b   Nagahiro, Shinji ^a,b   Munoz, Edwin L ^c   Lee, Lillian V ^c   Kaji, Ryuji ^a,b  

^a TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c Association of Philippine Medical Colleges   (Philippines)

Author keywords

neurodegeneration; neurogenesis; neuropeptide Y; striatum; X linked dystonia parkinsonism

Indexed keywords

CYCLINE; NEUROPEPTIDE Y;

ADULT; ARTICLE; BRAIN TISSUE; CAUDATE NUCLEUS; CELL DENSITY; CONTROLLED STUDY; DOPAMINE RELEASE; DYSTONIA; EXCITOTOXICITY; GENERALIZED DYSTONIA; GENETIC SCREENING; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERNEURON; MALE; NEOSTRIATUM; NERVE DEGENERATION; NERVE FIBER; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NUCLEUS ACCUMBENS; PARKINSONISM; PNEUMONIA; PRIORITY JOURNAL; PUTAMEN; STEM CELL; SUBVENTRICULAR ZONE; SUICIDE; TRANSCRIPTION INITIATION; X CHROMOSOME RECESSIVE DISORDER; X LINKED DYSTONIA PARKINSONISM;

EID: 84877246202     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt084     Document Type: Article

References (59)

1. Agasse F, Bernardino L, Kristiansen H, Christiansen SH, Ferreira R, Silva B, et al. Neuropeptide Y promotes neurogenesis in murine subventricular zone. Stem Cells 2008; 26: 1636-45.
2. Albin RL, Reiner A, Anderson KD, Penny JB, Young AB. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigid-akinesia. Ann Neurol 1990; 27: 357-65.
3. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogeneous precursors in the adult brain after stroke. Nat Med 2002; 9: 963-70.
4. Beal MF, Mazurek MF, Ellison DW, Swartz KJ, McGarvey U, Bird ED, et al. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann Neurol 1988; 23: 562-9.
5. Benarroch EE. Neuropeptide Y: its multiple effects in the CNS and potential significance. Neurology 2009; 72: 1016-20.
6. Burke RE, Baimbridge KG. Relative loss of striatal striosome compartment, defined by calbindin-D28k immunostaining, following developmental hypoxic-ischemic injury. Neuroscience 1993; 56: 305-15.
7. Caberlotto L, Fuxe K, Hurd YL. Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum. J Chem Neuroanat 2000; 20: 327-37.
8. Calabresi P, Centonze D, Pisani A, Sancesario G, Gubellini P, Marfia GA, et al. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol 1998; 43: 586-97.
9. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopainduced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010; 9: 1106-17.
10. Crittenden JR, Graybiel AM. Basal ganglia disorders associated with imbalances in the striosome and matrix compartments. Front Neuroanat 2011; 5: 59.
11. Curtis MA, Faull RLM, Eriksson PS. The effect of neurodegenerative diseases on the subventricular zone. Nat Rev Neurosci 2007; 8: 712-23.
12. Curtis MA, Penney EB, Pearson AG, van Roon-Mom WM, Butterworth NJ, Dragunow M, et al. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci USA 2003; 100: 9023-7.
13. Curtis MA, Penny EB, Pearson J, Dragunow M, Connor B, Faull RLM. The distribution of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington's disease human brain. Neuroscience 2005; 132: 777-88.
14. Dawbarn D, De Quidt ME, Emson PC. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res 1985; 340: 251-60.
15. Decressac M, Barker RA. Neuropeptide Y and its role in CNS disease and repair. Exp Neurol 2012; 238: 265-72.
16. Decressac M, Prestoz L, Veran J, Cantereau A, Jaber M, Gaillard A. Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. Neurobiol Dis 2009; 34: 441-9.
17. de Quidt ME, Emson PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system-II. Immunohistochemical analysis. Neuroscience 1986; 18: 545-618.
18. Feyder M, Bonito-Oliva A, Fisone G. L-DOPA-induced dyskinesias and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 2011; 5: 71.
19. Fuchs T, Saunders-Pullman R, Masuho I, Luciano MS, Raymond D, Factor S, et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet 2012; 45: 88-92.
20. Goto S, Hirano A, Matsumoto S. Met-enkephalin immunoreactivity in the basal ganglia in idiopathic Parkinson's disease and striatonigral degeneration. Neurology 1990; 40: 1051-6.
21. Goto S, Lee LV, Munoz EL, Tooyama I, Tamiya G, Makino S, et al. Functional anatomy of the basal ganglia in X-linked recessive dystonia-parkinsonism. Ann Neurol 2005; 58: 7-17.
22. Goto S, Nagahiro S, Kaji R. Striosome-matrix pathology of dystonias: a new hypothesis for dystonia genesis. In: Kurstot J, Forsstrom M, editors. Dystonia: causes, symptoms and treatment. New York: Nova Science Publishers; 2010. p. 1-22.
23. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990; 13: 244-54.
24. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci 2008; 31: 359-87.
25. Graybiel AM. Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000; 23 (Suppl): S71-7.
26. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001; 410: 940-4.
27. Hedreen JC, Folstein E. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995; 54: 105-20.
28. Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vitro evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington's disease. J Neurosci 2009; 29: 3200-5.
29. Holt DJ, Graybiel AM, Saper CB. Neurochemical architecture of the human striatum. J Comp Neurol 1997; 384: 1-25.
30. Jambaldorj J, Makino S, Munkhbat B, Tamiya G. Sustained expression of a neuron-specific isoform of the TAF1 gene in development stages and aging in mice. Biochem Biophys Res Commun 2012; 425: 273-7.
31. Jin K, Wang X, Xie L, Mao XO, Zhu W, Wang Y, et al. Evidence for stroke-induced neurogenesis in the human brain. Proc Natl Acad Sci USA 2006; 103: 13198-202.
32. Kubota Y, Kawaguchi Y. Spatial distributions of chemically identified intrinsic neurons in relation to patch and matrix compartments of rat neostriatum. J Comp Neurol 1993; 332: 499-513.
33. Lawhorn C, Smith DM, Brown LL. Striosome-matrix pathology and motor deficits in the YAC128 mouse model of Huntington's disease. Neurobiol Dis 2008; 32: 471-8.
34. Lee LV, Maranon E, Demaisip C, Peralta O, Borres-Icasiano R, Arancillo J, et al. The natural history of sex-linked recessive dystonia parkinsonism of Panay, Philippines (XDP). Parkinsonism Relat Disord 2002; 9: 29-38.
35. Lee LV, Pascasio FM, Fuentes FD, Viterbo GH. Torsion dystonia in Panay, Philippines. Adv Neurol 1976; 14: 137-51.
36. Makino S, Kaji R, Ando S, Tomizawa M, Yasuno K, Goto S, et al. Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet 2007; 80: 393-406.
37. Malva JO, Xapelli S, Baptista S, Valero J, Agasse F, Ferreira R, et al. Multifaces of neuropeptide Y in the brain-neuroprotection, neurogenesis and neuroinflammation. Neuropeptides 2012; 46: 299-308.
38. Miura M, Masuda M, Aosaki T. Roles of m-opioid receptors in GABAergic synaptic transmission in the striosome and matrix compartments of the striatum. Mol Neurobiol 2008; 37: 104-15.
39. Mü ller U. The monogenic primary dystonias. Brain 2009; 132: 2005-25.
40. Murer MG, Moratalla R. Striatal signaling in L-DOPA-induced dyskinesias: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation. Front Neuroanat 2011; 5: 51.
41. Noe F, Pool AH, Nissinen J, Gobbi M, Bland R, Rizzi M, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008; 131: 1506-15.
42. Nolte D, Niemann S, Mü ller U. Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism. Proc Natl Acad Sci USA 2003; 100: 10347-52.
43. Okita S, Morigaki R, Koizumi H, Nagahiro S, Kaji R, Goto S. Cell typespecific localization of optineurin in the striatal neurons of mice: implications for neuronal vulnerability in Huntington's disease. Neuroscience 2012; 202: 363-70.
44. Parent JM, Vexler ZS, Gong C, Derugin N, Ferriero DM. Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol 2002; 52: 802-13.
45. Perizzolo M, Winkfein B, Hui S, Krulicki W, Chan JA, Demetrick DJ. IDH mutation detection in formalin-fixed paraffin-embedded gliomas using multiplex PCR and single-based extension. Brain Pathol 2012; 22: 619-24.
46. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penny JB, Young AB. Differential loss of striatal projection neurons in Huntington's disease. Proc Natl Acad Sci USA 1988; 85: 5733-7.
47. Sato K, Kaji R, Matsumoto S, Nagahiro S, Goto S. Compartmental loss of striatal medium spiny neurons in multiple system atrophy of parkinsonian type. Mov Disord 2007; 22: 2365-70.
48. Sato K, Sumi-Ichinose C, Kaji R, Ikemoto K, Nomura T, Nagatsu I, et al. Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia. Proc Natl Acad Sci USA 2008; 105: 12551-6.
49. Smith Y, Parent A. Neuropeptide Y-immunoreactive neurons in the striatum of cat and monkey: morphological characteristics, intrinsic organization and co-localization with somatostatin. Brain Res 1986; 372: 241-52.
50. Stanić D, Paratcha G, Ledda F, Herzog H, Kopin AS, Hö kfelt T. Peptidergic influences on proliferation, migration, and placement of neural progenitors in the adult mouse forebrain. Proc Natl Acad Sci USA 2008; 105: 3610-5.
51. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982; 296: 659-60.
52. Tepper JM, Tecuapetla F, Koos T, Ibanez-Sandoval O. Heterogeneity and diversity of striatal GABAergic interneurons. Front Neuroanat 2010; 4: 150.
53. Thiriet N, Agasse F, Nicoleau C, Guegan C, Vallette F, Cadet J-L, et al. NPY promotes chemokinesis and neurogenesis in the rat subventricular zone. J Neurochem 2011; 116: 1018-27.
54. van den Pol AN. Neuropeptide transmission in brain circuits. Neuron 2012; 76: 98-115.
55. Wassarman DA, Sauer F. TAFII250: a transcription toolbox. J Cell Sci 2001; 114: 2895-902.
56. Waters CH, Faust PL, Powers J, Vinters H, Moskowitz C, Nygaard T, et al. Neuropathology of lubag (X-linked dystonia parkinsonism). Mov Disord 1993; 8: 387-90.
57. Woldbye DP, Angehagen M, Gotzsche CR, Elbrond-Bek H, Sorensen AT, Christiansen SH, et al. Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptor in the hippocampus suppresses seizures. Brain 2010; 133: 2778-88.
58. Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO. Neuropeptide Y as an endogeneous antiepileptic, neuroprotective and pro-neurogenic peptide. Recent Pat CNS Drug Discov 2006; 1: 315-24.
59. Zeron MM, Chen N, Moshaver A, Lee AT-C, Wellington CL, Hayden MR, et al. Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci 2001; 17: 41-53.